Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 5/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.56 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.55 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503413 | 0.88 | P2RY1 (0.67) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL17198341 | 0.84 | SLC29A1 (0.72) | SLC29A1SMN1; SMN2 | |
| SCHEMBL17198633 | 0.81 | TGM2 (0.69) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL17198595 | 0.80 | P2RY1 (0.78) | P2RY1P2RX3P2RX1P2RX4P2RY11 | |
| SCHEMBL26622787 | 0.80 | TGM2 (0.70) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL10048581 | 0.79 | P2RY1 (0.69) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL10017676 | 0.79 | P2RY1 (0.69) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL2619749 | 0.79 | P2RY1 (0.69) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL14625239 | 0.79 | P2RY1 (0.69) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL3502237 | 0.79 | P2RY1 (0.79) | P2RY1P2RX3P2RX1ENPP1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | P2RY1 536/4885P2RX3 988/4885P2RX1 1236/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | P2RY1 527/4885P2RX3 976/4885P2RX1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.